{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:32:11Z","timestamp":1790685131794,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias"},{"DOI":"10.13039\/501100004892","name":"Agencia Espa\u00f1ola de Cooperaci\u00f3n Internacional para el Desarrollo","doi-asserted-by":"publisher","award":["0000557290"],"award-info":[{"award-number":["0000557290"]}],"id":[{"id":"10.13039\/501100004892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005638","name":"Spanish Network for Research in Infectious Diseases","doi-asserted-by":"publisher","award":["RD06\/0008"],"award-info":[{"award-number":["RD06\/0008"]}],"id":[{"id":"10.13039\/501100005638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Fondo de Investigaci\u00f3n Sanitaria","award":["PI12_02376"],"award-info":[{"award-number":["PI12_02376"]}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ijantimicag.2015.07.007","type":"journal-article","created":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T13:30:04Z","timestamp":1439818204000},"page":"511-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["In vivo efficacy of voriconazole and posaconazole therapy in a novel invertebrate model of Aspergillus fumigatus infection"],"prefix":"10.1016","volume":"46","author":[{"given":"A.","family":"Forastiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bernal-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cendejas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gomez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0155","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0165","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.05088-11","article-title":"Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature","volume":"56","author":"Camps","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0175","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1128\/AAC.01331-12","article-title":"Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model","volume":"57","author":"Salas","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0180","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.riam.2012.09.002","article-title":"Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia","volume":"30","author":"Mellado","year":"2013","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0185","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3201\/eid1710.110226","article-title":"Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007\u20132009","volume":"17","author":"van der Linden","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0190","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0195","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/AAC.01279-12","article-title":"Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0200","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1128\/AAC.00606-10","article-title":"Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0205","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1128\/AAC.00931-09","article-title":"Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0210","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1128\/AAC.01436-12","article-title":"MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex","volume":"57","author":"Salas","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0215","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1371\/journal.ppat.0030101","article-title":"Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi","volume":"3","author":"Mylonakis","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0220","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/jac\/dkr198","article-title":"Wax moth larva (Galleria mellonella): an in vivo model for assessing the efficacy of antistaphylococcal agents","volume":"66","author":"Desbois","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0225","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1128\/AAC.01533-08","article-title":"Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics","volume":"53","author":"Peleg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0230","doi-asserted-by":"crossref","first-page":"e24485","DOI":"10.1371\/journal.pone.0024485","article-title":"Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection","volume":"6","author":"Garcia-Rodas","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/mmy\/myt022","article-title":"An invertebrate model to evaluate virulence in Aspergillus fumigatus: the role of azole resistance","volume":"52","author":"Gomez-Lopez","year":"2014","journal-title":"Med Mycol"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0240","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/13693786.2012.737031","article-title":"The non-mammalian host Galleria mellonella can be used to study the virulence of the fungal pathogen Candida tropicalis and the efficacy of antifungal drugs during infection by this pathogenic yeast","volume":"51","author":"Mesa-Arango","year":"2013","journal-title":"Med Mycol"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2015.07.007_bib0245","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.3109\/13693786.2010.523852","article-title":"Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice","volume":"49","author":"Slater","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0250","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijantimicag.2013.11.001","article-title":"Evaluation of Galleria mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection","volume":"43","author":"Hill","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0255","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ijantimicag.2012.12.009","article-title":"Galleria mellonella as a model system to test the pharmacokinetics and efficacy of antibiotics against Burkholderia pseudomallei","volume":"41","author":"Thomas","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0260","series-title":"EUCAST Definitive Document E.DEF 9.1: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds","author":"Rodriguez-Tudela","year":"2008"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0265","series-title":"Antifungal susceptibility testing (AFST): clinical breakpoints","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0270","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1469-0691.2011.03732.x","article-title":"HPLC\/UV or bioassay: two valid methods for posaconazole quantification in human serum samples","volume":"18","author":"Cendejas-Bueno","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eimc.2012.03.003","article-title":"Development and validation of a fast HPLC\/photodiode array detection method for the measurement of voriconazole in human serum samples. A reference laboratory experience","volume":"31","author":"Cendejas-Bueno","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0280","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jis372","article-title":"Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints","volume":"206","author":"Jeans","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0285","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11046-006-0021-1","article-title":"Susceptibility of larvae of Galleria mellonella to infection by Aspergillus fumigatus is dependent upon stage of conidial germination","volume":"161","author":"Renwick","year":"2006","journal-title":"Mycopathologia"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0290","series-title":"VFend\u00ae","author":"Pfizer Inc.","year":"2010"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/dkp416","article-title":"Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients","volume":"65","author":"Bruggemann","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.007_bib0300","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915002757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915002757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T01:59:31Z","timestamp":1537408771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915002757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0924857915002757"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.07.007","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo efficacy of voriconazole and posaconazole therapy in a novel invertebrate model of Aspergillus fumigatus infection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}